GLP-1 Prescriptions for Young Children Rose Sharply
The rate of GLP-1 prescriptions for children aged 8 to 11 increased 310-fold between 2019 and 2026.
Updated on Sept. 21, 2026 in Weight Loss
Live Poll
Do you trust the use of off-label weight-loss drugs for children under 12?
Annual prescribing of GLP-1 receptor agonists for children aged 8 to 11 climbed from 0.03% in 2019 to 9.3% in 2026. This data comes from a study analyzing electronic health records of more than 3.5 million children in the United States.
Why it matters
Families and clinicians are increasingly pursuing pharmacotherapy for children with severe obesity when traditional approaches fail. Some parents who use GLP-1 medications themselves may also be seeking similar treatment options for their children.
A study of 3.5 million children aged 8-11 found that 0.6% received GLP-1 prescriptions, which are currently FDA-approved for weight management starting at age 12. While safety data exists for daily liraglutide, no published data exists for semaglutide in this age group.
The players
Food and Drug Administration
The federal agency is responsible for protecting public health by ensuring the safety and efficacy of human drugs and medical devices.
The details
Doctors prescribe these medications off-label when they determine a medical rationale exists for patients with severe obesity and significant health complications. Data shows that children from less socially vulnerable areas were more likely to receive these prescriptions.
Timeline
In 2019, the annual prescribing rate for GLP-1 agonists in children aged 8 to 11 was 0.03%.
By 2026, the annual prescribing rate for the same age group rose to 9.3%.
Results for a large study on semaglutide use in children aged 6 to 11 are expected in November 2026.
The Big Picture
The rise in pediatric prescriptions marks a significant departure from the FDA's age-based approval threshold for weight management drugs.
Patients and caregivers should be aware that these medications are being prescribed off-label for children despite current FDA approval beginning at age 12. Clinicians are weighing these interventions only after standard weight management approaches for severe obesity have failed.
The takeaway
The trend toward early pharmacological intervention suggests a shift in how medical professionals manage childhood obesity. Families should consult with pediatric specialists to understand the risks and limited data regarding off-label medication use in young children.
What happens next
New study results regarding the use of semaglutide in children aged 6 to 11 are scheduled for presentation in November 2026.
Further reading
Learn more about evolving clinical approaches to pediatric obesity management in our Weight Loss section.
Live Poll
Do you trust the use of off-label weight-loss drugs for children under 12?
